Navigation Links
ULURU Inc. Reports First Quarter 2013 Financial Results
Date:5/16/2013

tantial risks and uncertainties, certain of which are beyond the Company's control. Any forward-looking statement speaks only as of the date on which such statement is made, and the Company undertakes no obligation to update any forward-looking statement or statements to reflect events or circumstances after the date on which such statement is made or to reflect the occurrence of an unanticipated event. Further, management cannot assess the impact of each such factor on the business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.
These statements are subject to numerous risks and uncertainties, including but not limited to the risk factors detailed in the Company's Annual Report on Form 10-K for the year ended December 31, 2012 and other reports filed by us with the Securities and Exchange Commission.

Contact: Company
Kerry P. Gray
President & CEO
Terry K. Wallberg
Vice President & CFO
(214) 905-5145 

 ULURU Inc.
SUMMARY OF RESULTS STATEMENTS OF OPERATIONS DATAThree Months Ended March 31,20132012REVENUESLicense fees

$
,153$
7,959Royalty income

---16,185Product sales, net

90,89135,861Total Revenues

102,04460,005COSTS AND EXPENSESCost of goods sold

40,88916,734Research and development

165,285192,960Selling, general and administrative

260,690476,299Amortization of intangible assets

117,161118,463Depreciation

65,38875,261Total Costs and Expenses

649,413879,717OPERATING (LOSS)(547,369)(819,712)Other Income (Expense)Interest and miscellaneous income

22,4651,654Interest expense

(131,686)(25,351)Equity in earnings (loss) of unconsolidated subsidiary

------(LOSS) Before Income Taxes(656,590)(843,409)Income taxes


'/>"/>
SOURCE ULURU Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. ULURU Inc. Announces Completion Of $2.2mil Convertible Debt Offering
2. ULURU Inc. Reports Second Quarter 2012 Financial Results
3. ULURU Inc. Announces First Order Of Altrazeal For European Launch
4. ULURU Inc. Announces The First Shipment Of Veterinary Product
5. ULURU Inc. Reports Third Quarter 2012 Financial Results
6. ULURU Inc. Announces Closing Of $440,000 Private Placement
7. ULURU Inc. Business Update And Outlook
8. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Fourth Quarter and Year Ended December 31, 2012 and to Provide a Business Update
9. ULURU Inc. Reports Financial Results For Fourth Quarter And Year Ending December 31, 2012
10. ULURU Inc. Announces Conference Call To Discuss Financial Results For The First Quarter Ended March 31, 2013
11. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com announces ... available in its catalogue: ... Forecast and Market Analysis to 2022 ... Atopic Dermatitis - India Drug Forecast and ...
(Date:1/15/2014)... , Jan. 15, 2014  Zafgen, Inc., a ... needs of severely obese patients, today announced initial ... a selective inhibitor of methionine aminopeptidase 2 (MetAP2), ... form of genetic obesity.  These results showed improvements ...
(Date:1/14/2014)... InformEx, North America,s leading business partnering ... the 30 th edition of its annual conference at ... January 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ) ... and specialty chemical companies will take part in the conference, ...
Breaking Medicine Technology:PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
... CVS Caremark Corporation (NYSE: CVS ), today announced ... ended September 30, 2011. (Logo: http://photos.prnewswire.com/prnh/20090226/NE75914LOGO) ... Net revenues increased 12.5% to a record $26.7 billion ... Retail Pharmacy segment revenues increased 3.8%, with same ...
... Bellicum Pharmaceuticals, Inc. today announced publication in ... results using a new therapy that demonstrated rapid and ... Inducible Apoptosis as a Safety Switch for Adoptive Cell ... ™ technology to eliminate donor T cells causing ...
Cached Medicine Technology:CVS Caremark Reports Third Quarter Results 2CVS Caremark Reports Third Quarter Results 3CVS Caremark Reports Third Quarter Results 4CVS Caremark Reports Third Quarter Results 5CVS Caremark Reports Third Quarter Results 6CVS Caremark Reports Third Quarter Results 7CVS Caremark Reports Third Quarter Results 8CVS Caremark Reports Third Quarter Results 9CVS Caremark Reports Third Quarter Results 10CVS Caremark Reports Third Quarter Results 11CVS Caremark Reports Third Quarter Results 12CVS Caremark Reports Third Quarter Results 13CVS Caremark Reports Third Quarter Results 14CVS Caremark Reports Third Quarter Results 15Bellicum Announces Publication in The New England Journal of Medicine Demonstrating Complete Reversal of Serious Immune Condition in Hematopoietic Stem Cell Transplant Patients 2Bellicum Announces Publication in The New England Journal of Medicine Demonstrating Complete Reversal of Serious Immune Condition in Hematopoietic Stem Cell Transplant Patients 3Bellicum Announces Publication in The New England Journal of Medicine Demonstrating Complete Reversal of Serious Immune Condition in Hematopoietic Stem Cell Transplant Patients 4
(Date:4/23/2014)... of endogenous neural precursor cells cannot alone compensate ... the perspective of neural plasticity, Dr. Yun Xiang ... observed the effects of functional electrical stimulation treatment ... of basic fibroblast growth factor and epidermal growth ... side. The researchers found that functional electrical stimulation ...
(Date:4/22/2014)... (Chicago) A recently FDA-approved device has been shown ... as much as 50 percent. When coupled with an ... Rush, the device facilitated the complete elimination of seizures ... in the decade-long clinical trials. , That,s good news ... in the U.S. living with epilepsy whose seizures can,t ...
(Date:4/22/2014)... all lung cancers are small cell lung cancers ... to chemotherapy. However, researchers at Virginia Commonwealth University ... the mechanisms leading to this resistance that may ... primarily by mediating B-cell lymphoma 2 (Bcl-2) family ... Depending on their function, this family of proteins ...
(Date:4/22/2014)... Hopkins scientists have found a way to block abnormal ... of atherosclerosis, the main cause of heart attacks and ... The condition develops when fat builds inside blood vessels ... greatly reducing their ability to feed oxygen-rich blood to ... series of experiments, described April 7 in the journal ...
(Date:4/22/2014)... massive health care spending, a new RAND study concludes ... incentivize pharmaceutical companies and device makers to develop products ... medical technologies and their use, a new study suggests ... medical devices get created in the first place. The ... as little loss of health as possible and to ...
Breaking Medicine News(10 mins):Health News:Newly approved brain stimulator offers hope for individuals with uncontrolled epilepsy 2Health News:Scientists pinpoint protein that could improve small cell lung cancer therapies 2Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 2Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 3Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 4Health News:US medical innovation needs smarter incentives to cut health spending, study finds 2Health News:US medical innovation needs smarter incentives to cut health spending, study finds 3
... (fool) has a lip smacking meaning here. Like Ekta ... nomenclature of the restaurants// here attracts customers. ... (Big Fool)", "Sabse Bada Bewakoof" (The Biggest Fool) and ... ,"The word 'bewakoof' is the only reason for ...
... An Israeli scientist wants to turn camel milk, a healthier ... desert.,The practised method of milking normally yields// some 1.5 litres ... the yield of 20 litres produced by cows. Yagil, however, ... 15 litres per camel a day. ,Traditionally seen ...
... organize a nationwide peaceful demonstration against the reservation quota in ... proposal to hike reservation seats started on the 27th April. ... by after the assembly poll in five states was not ... 2 will be a ‘‘show of strength’’ and send the ...
... in Angola to contain the cholera outbreak there says that 20,000 ... is an acute intestinal infection, which is caused in most cases ... It’s showing even more in other provinces now also. This week ... day and in some days more than 30 deaths," said Richard ...
... journal Nature has found that Gene therapy, which is used ... cancer//. US researcher, citing an animal study say that the ... than previously thought. ,However, experts from Great Ormond ... say that gene therapy in low doses does not cause ...
... the capital of India medical students are striking against ... new step when the students said that they are ... ,They were persuading school and college students to ... to increase the Other Backward Classes (OBC) quota in ...
Cached Medicine News:Health News:Milking the ship of the desert for 'white gold' 2Health News:Nationwide Strike on May 2nd by Medicos on Reservation Issue 2Health News:'Bubble Boy' Gene Therapy Causes Cancer? 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: